Imagin Medical Inc. (IMEXF)

[SO75]

Imagin Medical’s (CSE:IME; OTC:IMEXF) i/Blue Imaging System is expected to improve physicians’ ability to detect bladder cancer with minimally invasive endoscopes and reduce recurrence by dramatically improving the urologist’s ability to visualize, identify and remove cancerous cells.

“We have completed development of our prototype, an advanced optical and light sensor technology that, in conjunction with white light and near-infrared fluorescence, is expected to deliver superior images in less than 15 minutes, instead of the full hour required by conventional systems prior to use in the operating room,” Jim Hutchens, president and CEO, says in an interview with BioTuesdays. 

“We believe the time savings will increase the efficiency of the operating room and reduce healthcare costs by potentially enabling procedures to be performed in the less expensive setting of a physician’s office,” he adds.

And as the i/Blue Imaging System becomes established in the urology market, Mr. Hutc ithens says Imagin plans to complete development of the i/Vision Imaging System is technology, which combines multiple illumination sources into one system.

“The i/Vision will accommodate the most commonly used fluorescing contrast agents, such as indocyanine green (ICG), and would potentially enable Imagin to expand into additional specialties such as, general surgery, gynecology, colorectal and thoracic procedures,” he contends.

The current standard of care using endoscopes with white light has been used for decades and is ripe for innovation, Mr. Hutchens suggests. “White light is highly effective for visualizing cancerous tumors that protrude above the bladder wall, but is not as effective in visualizing their margins or tumors that lie flay on the bladder surface

http://www.biotuesdays.com/features/2018/6/12/imagin-medical-taking-bladder-cancer-imaging-to-next-level